PTC Therapeutics, Inc., acquires Emflaza (deflazacort) from Marathon Pharmaceuticals, LLC to treat Duchenne muscular dystrophy.
PTC Therapeutics, Inc. announced it has entered into an asset purchase agreement with Marathon Pharmaceuticals, LLC to acquire all rights to Emflaza (deflazacort). Emflaza is the first treatment approved in the United States for all Duchenne muscular dystrophy (DMD) patients five years and older, regardless of their genetic mutation. DMD is a rare and fatal genetic disorder that results in progressive muscle weakness from early childhood and leads to premature death due to heart and respiratory failure.
Emflaza aligns with PTC's mission to bring therapies to patients who have rare diseases with limited or no treatment options.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
3 mins